Archos: Its Subsidiary Dextrain Selected for the France 2030 Program
Archos announces that its subsidiary Dextrain, leading a consortium including Inserm and the research team of Professor Marie-Odile Krebs, has been selected for the France 2030 program. The NeuroScreen project aims to accelerate the diagnosis of psychiatric disorders through a digital solution that quantifies sensorimotor and neurocognitive markers.
Reducing Diagnostic Wandering and Optimizing Care
NeuroScreen employs digital technology to quantify sensorimotor and neurocognitive markers to more quickly distinguish early psychotic disorders from other pathologies, including autism and bipolar disorders. The project is set against a backdrop where over 30,000 patients consult annually in France for a first psychotic episode, and where diagnostic wandering is a critical factor for clinical prognosis.
The standardization of assessments reduces the administration time by 30%, eliminating diagnostic bottlenecks. This improvement increases the overall capacity of services by 10 to 15% without additional resources, while initiating targeted and early intervention.
Medico-Economic Benefits and Prevention Model
By facilitating early intervention, NeuroScreen aims to save the Health Insurance system between €32,000 to €48,000 per patient over five years by avoiding emergency hospitalizations (average cost of €16,000 per episode).
The project transforms mental health management from a reactive to a preventive approach. By integrating systematic monitoring over two years and identifying the most vulnerable adolescents during prevention campaigns, NeuroScreen enables immediate intervention to prevent the onset of the disease and thus avoid emergency hospitalizations. The consortium includes Dextrain (leader), Inserm, and the research team of Professor Marie-Odile Krebs.
